The specific aims Of this study will include quantifying longitudinal changes in the tone Of the dopaminergic nervous system with neuroimaging techniques in patients with Parkinson's disease who are treated with adjunctive subthalamic nucleus (STN) stimulation. The findings will be compared to outcome in patients treated with pallidotomy Or conventional medications alone. Long-term outcome in each of these groups will be assessed with neuropsychological tests, clinical rating scales administered by research neurologists, and repeated measurements of dopamine transporter concentrations. Transporter concentrations will be estimated with an award-winning, technetium-99m labeled imaging agent that can accurately distinguish patients with Parkinson's disease from matched controls. Appropriate asymmetries can be detected in young, recently diagnosed patients with Hami-Parkinson's. At a cost of only pennies per milliCurie, the data clearly demonstrate that the uptake values of [Tc-99m]TRODAT-1 are significantly related to several neuropsychological task performance scores that are known to be partially mediated by dopamine in both patients and controls. The study has been designed as a multi-arm clinical trial. In patients, simultaneous measurements of transporter concentrations and neuropsychological test performance will be performed by blinded investigators two weeks before surgery, and then repeated at six (6) month intervals over the next three (3) years. In matched controls, the same protocol will be performed at two-week intervals once each year for three years. Both fully automated statistical parametric mapping and rigorous MRI coregistration image analysis techniques will be used to correlate physiology with behavior while controlling f9r aging as a confounding covariate. The results may be clinically relevant for several reasons. Parkinson's disease remains a relatively common and potentially devastating problem. Subthalamic nucleus stimulation seems to be a particularly promising approach in some patients. Chronic inhibition of the glutaminergic neurons projecting from the subthalamus may protect, if not actually rescue, dopaminergic neurons. While there is already some strong support for its effectiveness, it is not risk-free, and an objective measure of relevant physiology that reflects the response of the human brain to chronic subthalamic nucleus stimulation has not been reported. This study will provide that data while pursuing a long-term goal of developing a more effective and economical method for objectively assessing the outcome of an new treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG017524-02
Application #
6349744
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Finkelstein, Judith A
Project Start
2000-02-15
Project End
2005-01-31
Budget Start
2001-02-01
Budget End
2002-01-31
Support Year
2
Fiscal Year
2001
Total Cost
$356,283
Indirect Cost
Name
University of Pennsylvania
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Amsterdam, Jay D; Newberg, Andrew B; Newman, Cory F et al. (2013) Change over time in brain serotonin transporter binding in major depression: effects of therapy measured with [(123) I]-ADAM SPECT. J Neuroimaging 23:469-76
Newberg, Andrew B; Amsterdam, Jay D; Wintering, Nancy et al. (2012) Low brain serotonin transporter binding in major depressive disorder. Psychiatry Res 202:161-7
Amsterdam, Jay D; Newberg, Andrew B; Soeller, Irene et al. (2012) Greater striatal dopamine transporter density may be associated with major depressive episode. J Affect Disord 141:425-31
Crits-Christoph, Paul; Newberg, Andrew; Wintering, Nancy et al. (2008) Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend 98:70-6
Amsterdam, Jay D; Newberg, Andrew B (2007) A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology 55:167-70
Newberg, Andrew; Amsterdam, Jay; Shults, Justine (2007) Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nucl Med Commun 28:3-6
Newberg, Andrew; Lerman, Caryn; Wintering, Nancy et al. (2007) Dopamine transporter binding in smokers and nonsmokers. Clin Nucl Med 32:452-5
Acton, Paul D; Newberg, Andrew; Plossl, Karl et al. (2006) Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol 51:575-85
Acton, Paul D; Newberg, Andrew (2006) Artificial neural network classifier for the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol 51:3057-66
Newberg, Andrew B; Amsterdam, Jay D; Wintering, Nancy et al. (2005) 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 46:973-7

Showing the most recent 10 out of 18 publications